Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case–control study on survival in patients with two year follow-up

 Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case–control study on survival in patients with two year follow-up

Highlights

► In this study, post-relapse survival and duration of secondary response is longer in recurrent platinum-sensitive cases treated with SCR plus HIPEC (Cases).
► These data are statistically significant when compared to a similar group of women not experimenting HIPEC (Controls).
► The combined management, cytoreductive surgery plus HIPEC followed by systemic chemotherapy, might be the treatment of choice in selected recurrent platinum-sensitive patients.

Abstract

Objectives

To compare survival data in platinum sensitive recurrent ovarian cancer patients submitted to secondary cytoreduction (SCR) plus hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) (Cases) and a similar group of women not experiencing HIPEC (Controls).

Methods

Case–control study, matching 37 Cases with 37 Controls, with at least 24 months of follow up.

Results

Groups were comparable for all characteristics, except for a higher proportion of patients with single-nodule relapses is the Controls (19 vs. 6; p = 0.011). Median follow up time was 46 months in the Cases and 36 months in the Controls. Twenty patients (66.6%) experienced secondary recurrence in the Cases and 37 women (100%) in the Controls (p = 0.001). Moreover, 7 (23.3%) and 23 (62.2%) patients died of disease in the Cases and Controls respectively (p = 0.003). The duration of secondary response was 26 months in the Cases and 15 months in the Controls (p = 0.004).

Conclusions

The combination of SCR and HIPEC seems to improve survival rate in patients suffering from platinum-sensitive EOC recurrence with respect to no-HIPEC treatments. This result further supports the need of a randomized trial.

---

Highlights

► In this study, post-relapse survival and duration of secondary response is longer in recurrent platinum-sensitive cases treated with SCR plus HIPEC (Cases).
► These data are statistically significant when compared to a similar group of women not experimenting HIPEC (Controls).
► The combined management, cytoreductive surgery plus HIPEC followed by systemic chemotherapy, might be the treatment of choice in selected recurrent platinum-sensitive patients.